Drug intelligence / Profile preview

emodepside + praziquantel

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Topical, Oral
01

Overview

**Emodepside + praziquantel** is a fixed-dose combination antiparasitic veterinary drug marketed under the brand name Profender. It is indicated for the treatment and control of mixed intestinal worm infections (nematodes and cestodes) in cats and dogs. **Emodepside** is a semi-synthetic depsipeptide active against nematodes such as roundworms (e.g., ascarids) and hookworms. It acts at the neuromuscular junction by stimulating presynaptic secretin receptor family receptors, causing paralysis and death of the worms. **Praziquantel** is a pyrazinoisoquinoline derivative effective against tapeworms (cestodes); it acts by altering calcium permeability in the parasite membrane, leading to muscular contraction, paralysis, and death of the tapeworm[3][4][7]. The combination is applied topically (spot-on solution) in cats and orally (tablets) in dogs, depending on regional approvals. Profender is approved for use in the US for cats and in Europe for both cats and dogs[4][5]. It is marketed for veterinary use only and targets infections with organisms such as Toxocara spp., Ancylostoma spp., Dipylidium caninum, and Taenia spp. The combination is well tolerated, with adverse events mainly mild and transient[1][7].

Other names
emodepside/praziquantelProfender spot-onProfender tablets
02

Targets

LPHN (Latrophilin receptor family)KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)VDCC (L-type voltage-dependent calcium channel (often specified further as subunits such as CaV1.2 in humans))

Beyond the preview

Go deeper on emodepside + praziquantel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on emodepside + praziquantel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call